Physician profile
Young Kim
NPI 1831695667
$10,905.15
in general payments reported to CMS, 2019-2025
62 companies · $5,829 in 2025
The $5,829 reported for 2025 was more than what 75% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2024: $4,951 · 2025: $5,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,043.11 |
| Education | $737.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $659.69 | 2024-2025 | Monjuvi, Jakafi, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $602.28 | 2024-2025 | Fruzaqla, Ninlaro, Iclusig |
| Astellas Pharma US INC | $588.07 | 2024-2025 | Xospata, Vyloy |
| Janssen Biotech, INC. | $564.81 | 2024-2025 | Rybrevant, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $477.21 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Gilead Sciences, INC. | $467.76 | 2024-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $441.45 | 2024-2025 | Zejula, Ojjaara, Jemperli |
| Sobi, INC | $424.31 | 2024-2025 | Vonjo, Doptelet, Gamifant |
| Novartis Pharmaceuticals Corporation | $383.69 | 2025 | |
| Pfizer INC. | $362.27 | 2024-2025 | |
| Abbvie INC. | $343.06 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $338.52 | 2021-2025 | Imfinzi, Enhertu |
| Lilly USA, LLC | $324.43 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $296.88 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Eisai INC. | $281.46 | 2024-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $265.31 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Blueprint Medicines Corporation | $263.29 | 2024-2025 | Ayvakit |
| Exelixis INC. | $223.19 | 2024-2025 | Cabometyx |
| Genentech USA, INC. | $210.96 | 2024-2025 | Phesgo, Polivy, Itovebi |
| Puma Biotechnology, INC. | $209.73 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $207.22 | 2024-2025 | |
| Celgene Corporation | $197.81 | 2024-2025 | Reblozyl, Pomalyst, Opdivo |
| Taiho Oncology, INC. | $172.45 | 2024-2025 | |
| Boston Scientific Corporation | $166.84 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| E.R. Squibb & Sons, L.L.C. | $163.03 | 2024-2025 | Opdivo, Opdualag |
| Deciphera Pharmaceuticals INC. | $162.93 | 2024-2025 | Qinlock, Tgct, Romvimza |
| Stemline Therapeutics INC. | $148.10 | 2024-2025 | Orserdu |
| Genzyme Corporation | $130.86 | 2024-2025 | |
| Geron Corporation | $120.99 | 2025 | Rytelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.59 | 2024-2025 | Gilotrif |
| Beigene USA, INC. | $115.41 | 2024-2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $112.98 | 2024-2025 | Libtayo |
| Pharmaessentia USA Corporation | $103.63 | 2024-2025 | Besremi |
| Octapharma USA, INC. | $92.25 | 2024-2025 | Octagam Immune Globulin (Human) |
| Genmab U.S., INC. | $90.73 | 2024-2025 | Epkinly |
| Coherus Oncology, INC. | $86.14 | 2024-2025 | Loqtorzi |
| Emd Serono, INC. | $81.86 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $81.29 | 2025 | Xpovio |
| Pharmacosmos Therapeutics INC. | $74.65 | 2024-2025 | Monoferric, Cosela |
| Novocure INC. | $66.57 | 2025 | Optune Lua (Novottf-200t), Optune Gio |
| Aveo Pharmaceuticals, INC. | $65.93 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $54.63 | 2024 | Orgovyx |
| Mirati Therapeutics, INC. | $50.75 | 2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $47.08 | 2024 | Somatuline Depot, Onivyde |
| Agios Pharmaceuticals, INC. | $45.92 | 2024-2025 | Pyrukynd |
| Iovance Biotherapeutics, INC. | $45.88 | 2025 | Amtagvi |
| Rigel Pharmaceuticals, INC. | $42.98 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Beone Medicines USA, INC. | $33.29 | 2025 | Brukinsa |
| Tersera Therapeutics LLC | $32.21 | 2025 | Zoladex |
| Springworks Therapeutics, INC. | $27.27 | 2024 | Ogsiveo |
| Immunocore Limited | $25.84 | 2025 | Kimmtrak |
| Tolmar, INC. | $25.14 | 2024 | |
| Legend Biotech USA INC. | $20.82 | 2025 | Carvykti |
| Recordati_rare_diseases_inc. | $20.77 | 2024 | Sylvant |
| Tempus Ai, INC | $20.57 | 2024 | |
| Progenics Pharmaceuticals, INC. | $20.03 | 2025 | |
| Kyowa Kirin, INC. | $19.37 | 2025 | |
| Telix Pharmaceuticals | $18.78 | 2025 | Illuccix |
| Jazz Pharmaceuticals INC. | $17.89 | 2025 | |
| Spectrum Pharmaceuticals INC. | $17.20 | 2024 | Rolvedon |
| Servier Pharmaceuticals LLC | $16.42 | 2025 | |
| Shorla Oncology INC. | $14.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.